Alterity Therapeutics Ltd
Alterity Therapeutics Receives Positive FDA Feedback for ATH434 Phase 3 MSA Program
Alterity Therapeutics wins positive FDA feedback on ATH434 Phase 3 for MSA; End-of-Phase 2 meeting mid-2026; cash runway ~A$49.2m.
Alterity Therapeutics Confirms Effectiveness of ATH434 Drug Against Advanced MSA
Alterity Therapeutics (ASX: ATH) has released positive topline data from an open label Phase 2 clinical trial of lead candidate ATH434 on 10 patients with advanced multiple system atrophy (MSA). Data from the ATH434-202 trial showed the oral drug conferred a clinical benefit on areas of impairment in MSA and was able to stabilise key […]
Alterity Therapeutics shows positive ATH434 Phase 2 trial results for Multiple System Atrophy
Alterity Therapeutics (ASX: ATH) has announced positive topline results from a Phase 2 clinical trial of lead candidate ATH434-201 on patients with early-stage multiple system atrophy (MSA). ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. MSA is a rare neurodegenerative disease characterised by failure of the autonomic […]
Alterity Therapeutics’ ATH434 trial results suggest improved outcomes for MSA Patients
Alterity Therapeutics (ASX: ATH) has released positive interim data from an open-label Phase 2 clinical trial of its lead asset ATH434, showing stable or improved neurological symptoms in patients with multiple system atrophy (MSA). The analysis of a total of ten participants included clinical and biomarker data on seven who were treated with daily oral […]